Educational content on VJRegenMed is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

Meeting on the Med 2022 | Plasmacytoid dendritic cell-based cancer vaccines

Eric Halioua • 20 Apr 2022
Meeting on the Med 2022
Solid Tumors

Eric Halioua, PDC*line Pharma, Liege, Belgium, provides an overview of PDC*line, a novel cell line derived from plasmacytoid dendritic cells (PDCs) in the bones of patients with leukemia. The cell line is more potent than allogeneic or autologous myeloid cells and are not rejected in humans. He additionally highlights the ease of manufacturing cancer vaccines from PDC*line due to the consistency of the cell line. This interview was conducted during Meeting on the Mediterranean 2022.

More from Eric Halioua

2:41
Developing a therapeutic cancer vaccine for patients with NSCLC
Eric Halioua • 20 Apr 2022
1:34
Assessing PDC*mel, dendritic cell-based vaccine in melanoma
Eric Halioua • 20 Apr 2022

Related Videos

2:41
Developing a therapeutic cancer vaccine for patients with NSCLC
Eric Halioua • 20 Apr 2022
1:34
Assessing PDC*mel, dendritic cell-based vaccine in melanoma
Eric Halioua • 20 Apr 2022
4:06
Optimizing the upscaling and outscaling of CAR T-cell therapies
Saskia Rösch • 6 Apr 2022
1:23
Enhancing the long-term functionality of CAR-T cells in solid tumors
Shigeki Yagyu • 8 Apr 2022
The content of VJRegenMed is intended for healthcare professionals